Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Ausbruch – startet jetzt die massive FDA-Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QLX7 | ISIN: US4884452065 | Ticker-Symbol: 1GDA
Tradegate
16.04.24
13:18 Uhr
4,580 Euro
+0,220
+5,05 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ZEVRA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ZEVRA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,2604,40017.04.
4,2804,44017.04.

Aktuelle News zur ZEVRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoZevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting23The oral presentation highlighted data from Zevra's Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc....
► Artikel lesen
10.04.Zevra Therapeutics retires existing debt with new $100M credit facility1
10.04.ZEVRA THERAPEUTICS, INC. - 8-K, Current Report2
10.04.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility86CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into...
► Artikel lesen
01.04.ZEVRA THERAPEUTICS, INC. - 10-K, Annual Report1
01.04.Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript2
01.04.Earnings call: Zevra Therapeutics reports progress and financials for Q4 20233
29.03.Zevra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary2
28.03.Zevra Therapeutics: Q4 Earnings Insights2
28.03.Zevra Therapeutics GAAP EPS of -$1.30 misses by $0.12, revenue of $27.46M beats by $1.48M3
28.03.ZEVRA THERAPEUTICS, INC. - 8-K, Current Report2
28.03.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates455Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M...
► Artikel lesen
27.03.Earnings Outlook For Zevra Therapeutics1
26.03.Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia224KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) --...
► Artikel lesen
25.03.Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference1
18.03.EU-Projekt ZEvRA: Fraunhofer IWU entwickelt mit Partnern Recycling-Lösungen für kreislauffähiges Elektroauto5
18.03.Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 20243
12.03.Zevra adds bull at William Blair despite delay in arimoclomol decision2
04.03.Zevra Therapeutics down as FDA extends review for genetic disorder treatment5
04.03.Zevra Therapeutics Says FDA Extends NDA Review Period For Arimoclomol4
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1